学校主页
首页 > 学术报告
 报告题目: Exploration of Nanoparticles Based Photodynamic Therapy For Deep Cancer Treatment
  
 开始时间: 2018-07-24 14:30:00
  
 报告地点: 实验一楼第二会议室
  
 报 告 人: 德州大学陈伟教授
  
 主办单位: 材料科学与工程学院
  
 备    注:

报告人介绍:

    陈伟(Wei Chen)博士,德克萨斯大学Arlington分校(The University of Texas at Arlington, UTA)物理系纳米生物物理专业终身正教授。曾获中科院杰出青年科学家奖、教育部科技进步奖、北京大学科技成果奖。两次次获得德州大学科研优秀奖,两次提名德州杰出科学家。2017年获得美国科技出版社最佳论文奖。现担任生物医学纳米技术杂志(Journal of Biomedical Nanotechnology)副主编,美国科学出版社(American Scientific Publishers, California)主编,纳米科学与技术评论杂志(Reviews in Nanoscience and Nanotechnology)主编。

    他多年来一直从事纳米技术的尖端研究,系国际著名纳米药物和癌症纳米技术专家。率先提出纳米颗粒自发光光动力学治疗癌症的概念、在纳米颗粒的热释发光和光激励发光(PSL)及其在放射治疗中的应用研究上一直处于世界领先地位。研究团队最近研究出的一种新的光动力纳米药,可以被X-光、微波、超声及紫外光激发,在癌症治疗中展现了极好的应用前景;与合作者发明的微波激活的光动力学治疗,引起纳米技术行业和医学领域的关注,获得了国际学术界很高评价。作为项目负责人,获得20项、共计约800万美元创新研究基金。发表SCI论文240多篇,被引用超过10000次,其中单篇最高引用632次,22篇文章被引用超过100次,H因子为49。

    

报告内容简介:

    Photodynamic therapy (PDT) is a promising modality for cancer treatment but just limited for skin diseases. Light must be delivered in order to activate photodynamic therapy. Most photosensitizers have strong absorption in the ultraviolet (UV)-blue range, therefore, UV-blue light is needed for their activation. Unfortunately, UV-blue light has minimal penetration into tissue and its application for in vivo activation is a problem. To solve the problem and enhance the PDT treatment for deep cancers, we introduce new PDT systems in which the light is generated by afterglow nanoparticles with attached photosensitizers. When the nanoparticle-photosensitizer conjugates are targeted to tumor, the light from afterglow nanoparticles will activate the photosensitizers for photodynamic therapy. Therefore, no external light is required for treatment. More importantly, it can be used to treat deep tumor such as breast cancer because the light source is attached to the photosensitizers and are delivered to the tumor cells all together. This new modality is refereed as Nanoparticle Self-Lighting Photodynamic Therapy (NSLPDT). Most recently, we invented a new sensitizer called copper cysteamine that can be activated by light, X-rays, microwave and ultrasound to produce singlet oxygen for cancer treatment. This opens a new door for photodynamic therapy in combination with radiotherapy, microwave ablation and sonodynamic therapy for cancer treatment.